A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

A composition is provided comprising a therapeutically active amount of vitamin K for administering to a subject as prophylactic for preventing or reducing the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease, or as therapeutic for preventing said disease becoming more severe or reducing the severity of said disease. Also provided is a diagnostic test to estimate the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease in a subject involving assessing vitamin K status in blood, serum or plasma of said subject.

A composition is provided comprising a therapeutically active amount of vitamin K for administering to a subject as prophylactic for preventing or reducing the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease, or as therapeutic for preventing said disease becoming more severe or reducing the severity of said disease. Also provided is a diagnostic test to estimate the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease in a subject involving assessing vitamin K status in blood, serum or plasma of said subject.

A composition is provided comprising a therapeutically active amount of vitamin K for administering to a subject as prophylactic for preventing or reducing the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease, or as therapeutic for preventing said disease becoming more severe or reducing the severity of said disease. Also provided is a diagnostic test to estimate the risk of developing severe disease or mortality by COVID-19 or a similar infectious disease in a subject involving assessing vitamin K status in blood, serum or plasma of said subject.

Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.